Biotech firms tend to come on to SPACs’ radar when they still have some clinical work to complete to get to an approved medicine or device, but Avertix is ahead of that particular curve.
This week, we speak with Tim Moran, President and CEO of Avertix, and Ross Haghighat, CEO and CFO of BioPlus Acquisition Corp. (Nasdaq: BIOS). The two announced a $195 million dollar combination in May of this year.
Tim tells us how Avertix’s Guardian heart monitoring implant has performed in its initial commercial rollout, having already been approved by the FDA and for insurance reimbursements.
Ross meanwhile explains why being at that stage of the process was important for BioPlus’ criteria given the current market conditions and what further value streams could be unlocked by the Guardian device long term.
Give it a listen
Alpha Star (NASDAQ:ALSA) has entered into a definitive agreement to combine with fintech firm XDATA at an equity value of $180 million. Tallinn, Estonia-based XData provides payment software and digital banking systems for business clients. The combined company is expected to trade on the Nasdaq once the deal is completed in late 2024. Transaction Overview...
At the SPAC of Dawn The market shifted this week on the see-saw of the US election prospects, but, beyond the policies at play, another impact the election could have on the SPAC market is the potential for a fair amount of people movement. Many of the biggest names in SPACland have been bundling donations...
At the SPAC of Dawn After what appeared to a pause in activity around the presidential debate, Southport (OTC:PORT) and Future Vision II (NASDAQ:FVNNU) broke the seal yesterday on both new business combinations and IPOs, respectively. Two SPACs are about to come off of the board as well, however, as 99 Acquisition Group (NASDAQ:NNAG) has...
Future Vision II Acquisition Corp. announced the pricing of its $50 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “FVNNU”, Friday, September 12, 2024. The new SPAC intends to focus its search on businesses within the technology, media, and telecommunications sector. Future Vision II’s sponsor team is...
Southport (OTC:PORT) has entered into a definitive agreement to combine with Angel Studios at a pro forma enterprise value of $1.56 billion. Angel Studios produces film and TV content for both streaming and theatrical releases. The combined company is expected to trade on the NYSE or Nasdaq under the symbol “AGSD” once the deal is...